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México:  ¿son  la  azitromicina  más  levo
Helicobacter  pylori  (H.  pylori) infection  is  an  important
causal  factor  in  chronic  gastritis,  peptic  ulcer  disease,  gas-
tric  mucosa-associated  lymphoid  tissue  lymphoma  (MALT
tumor),  and  gastric  cancer.1 Thus,  scientific  societies  rec-
ommend  eradicating  the  ‘‘bug’’  in  well-defined  clinical
situations.  The  standard  triple  therapy  of  a  proton  pump
inhibitor  (PPI),  amoxicillin,  and  clarithromycin  administered
for 7--14 days  has  been  used  for  many  years.  However,  the
efficacy  of  that  regimen  has  decreased  to  values  below  80%
in  many  countries  due  to  an  increase  in  the  prevalence  of
clarithromycin  resistance.  Therefore,  clarithromycin-based
triple  therapy  is  not  currently  recommended,  unless  a  resis-
tance  rate  to  clarithromycin  below  15%  is  documented.2--5
On  the  other  hand,  levofloxacin-based  triple  therapy,
combined  with  a  PPI  and  amoxicillin,  has  been  reported  as  an
effective  first-line  alternative,  as  well  as  being  considered
an  option  for  salvage  therapy.6,7 However,  the  primary  resis-
tance  rate  to  levofloxacin  has  increased  in  many  countries
due  to  its  generalized  use.8--10 More  recent  studies,  includ-
ing  one  conducted  in  Mexico,  have  shown  that  the  efficacy
of  triple  therapy  with  fluoroquinolones  varies  widely,  from
70  to  90%,  limiting  its  efficacy  with  respect  to  initial
reports.11--13
The  authors  of  a  meta-analysis  reported  eradication
rates  of  80%  for  levofloxacin-based  therapy  and  of  77%
for  clarithromycin-based  therapy,  showing  no  significant
differences  between  the  two  regimens.14 In  a  more
recent  meta-analysis  of  178  studies  from  68  countries,
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5%  in  all  the  regions,  with  a  significant  reduction  in  par-
llel  with  the  H.  pylori  eradication  rate,  with  the  exception
f  Europe  (11%,  95%  CI:  9-13).  In  that  same  study,  clar-
thromycin  resistance  rates  above  15%  were  reported  in  all
he  regions,  except  Southeast  Asia  and  the  Americas.15 In  a
ord,  the  efficacy  of  that  triple  therapy  is  below  80%  in  many
ountries,  and  so  its  empiric  use  should  not  be  recommended
hen  the  levofloxacin  resistance  rate  is  above  5-10%.12
The  analyzed  use  of  azithromycin  has  been  reported  as
n  effective  alternative.  Nevertheless,  studies  have  shown
hat  eradication  rates  vary  widely,  from  22  to  93%.16--18 That
isparity  may  be  partially  due  to  alterations  in  azithromycin
bsorption  and  to  the  cross-resistance  of  azithromycin  with
ther  macrolides.19,20 In  a  meta-analysis  of  14  studies,  Dong
t  al.  reported  an  eradication  rate  of  80%  for  therapy
ith  azithromycin,  with  an  acceptable  frequency  of  adverse
ffects.  Even  though  those  rates  are  barely  satisfactory,  it
hould  be  stated  that  most  of  the  studies  included  are  from
egions  with  a prevalence  of  clarithromycin  resistance  above
5%.15,20 In  a  recent  Italian  randomized  clinical  trial,  therapy
ased  on  azithromycin  and  levofloxacin  for  7  days  was  com-
ared  with  standard  triple  therapy  with  clarithromycin  for  7
ays,  obtaining  eradication  rates  of  70%  and  76%,  respec-
ively.  Both  values  are  below  acceptable  figures  and  no
ifference  in  treatment  adherence  was  observed.  We  should
larify  that  the  results  are  from  an  area  in  which  prevalence
f  resistance  to  clarithromycin  is  above  15%  and  levofloxacin
esistance  is  from  10-15%.15,21  That  information  under-
ines  the  difference  in  resistance  rates  by  geographic  region,
ts  impact  on  eradication,  and  the  difficulty  in  select-
ng  an  adequate  empiric  regimen,  emphasizing  the  need
or  decisions  to  be  based  on  an  analyzed  local  resistance
attern.21
Given  those  arguments,  we  believe  the  publishing  of  the
esults  of  an  experimental  clinical  trial  conducted  in  Mexico


































































n  this  issue  of  the  Revista  de  Gastroenterología  de  Méx-
co  is  opportune.  The  trial  compared  a  triple  regimen  based
n  azithromycin  and  levofloxacin  with  the  standard  triple
herapy  with  clarithromycin,  searching  for  a  non-inferiority
ontrast  in  the  cure  rate  between  the  two  regimens,  both  of
hich  were  administered  for  10  days.  The  study  had  an  ade-
uate  number  of  subjects  (n  =  227)  and  eradication  rates
f  63%  in  the  azithromycin/levofloxacin  group  and  58.5%
n  the  clarithromycin/amoxicillin  group  were  reported.  The
uthors  corroborated  the  elevated  clarithromycin  resistance
ate  in  Mexico,  which  was  28.2%  in  their  cohort.  Unfortu-
ately,  they  did  not  characterize  azithromycin  resistance.
he  only  difference  between  the  study  groups  was  in  the
dverse  effect  rate,  which  was  higher  in  the  clarithromycin
roup  at  86%,  compared  with  65%  in  the  azithromycin  group
p  =  0.001).22
Regrettably,  both  eradication  rates  were  below  that  sug-
ested  in  the  current  clinical  guidelines  and  were  similar
o  results  reported  in  other  recent  studies.15,22--25 As  with
he  standard  triple  therapy  with  clarithromycin,  the  infer-
nce  is  that  azithromycin-based  triple  therapy  should  not
e  used  in  areas  with  clarithromycin  resistance  above  15%.
exico  is  such  an  area,  with  rates  on  the  rise.  Said  resistance
an  be  explained  by  the  fact  that  macrolides  are  the  most
requently  prescribed  antibiotics  in  the  United  States,  and
erhaps  in  Mexico  as  well.26 Thus,  we  suggest  that  it  is  essen-
ial  to  implement  local  surveillance  networks  that  provide
he  information  for  appropriately  selecting  more  effective
radication  regimens  in  each  region.
Mexico  is  a  heterogeneous  country  with  limited  infra-
tructure  and  access  in  many  zones,  making  that  type  of
esearch  very  difficult  to  carry  out.  Therefore,  we  believe
t  is  relevant  to  point  out  another  option.  That  alternative
ould  be  to  replicate  the  recently  published  experience  of
 group  of  researchers  from  Taiwan  who  compared  the  effi-
acy  of  therapy  guided  by  the  genotypic  resistance  pattern
f  H.  pylori  with  empiric  therapy  based  on  the  history  of
revious  antibiotic  exposure,  in  a  group  of  patients  in  whom
 or  more  eradication  regimens  had  failed.27 The  therapy
ased  on  the  resistance  pattern  achieved  a  cure  in  78%  of
he  patients,  whereas  the  cure  rate  was  72%  in  the  empiric
reatment  group,  with  no  statistically  significant  difference.
hose  results  suggest  that  empiric  management  based  on
he  history  of  medications  used  in  the  past  could  be  a  prac-
ical  and  effective  alternative,  as  well  as  a  cost-efficient
nd  accessible  option.
onclusions
 H.  pylori  resistance  to  antibiotics  has  reached  alarming
levels  worldwide,  which  has  a  great  effect  on  treat-
ment  efficacy.  Local  surveillance  networks  are  required  to
select  appropriate  eradication  regimens  for  each  region.
 Clarithromycin-based  triple  therapy  is  not  recommended
unless  the  local  clarithromycin  resistance  rate  is  below
15%.
 Empiric  first-line  therapy  should  be  a  14-day  course  of
bismuth  or  antibiotic-based  quadruple  therapy.
 The  efficacy  of  levofloxacin-based  triple  therapy  has  been
lower  than  80%  in  many  countries  and  is  not  recommended
when  levofloxacin  resistance  is  higher  than  5-10%.EDITORIAL
 However,  a properly  designed  empiric  therapy,  based  on
medication  history,  is  an  acceptable  alternative  to  geno-
typic  resistance-guided  therapy  for  the  eradication  of
refractory  H.  pylori  infection  after  considering  accessi-
bility,  cost,  and  patient  preference.
 Second-line  therapy  should  be  determined  in  relation  to
the  first-line  therapy  that  failed.
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